Myriad Genetics

Myriad Genetics

Yahoo Finance • 13 days ago

3 Healthcare Stocks with Open Questions

3 Healthcare Stocks with Open Questions Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only ri... Full story

Yahoo Finance • 18 days ago

MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Myriad (MYGN) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Myriad and would like to discus... Full story

Yahoo Finance • 18 days ago

Endometrial Cancer Market Share Analysis and Industry Trends (2026-2031) Featuring Merck, Eisai, Karyopharm Therapeutics, Context Therapeutics, Seagen and More

Company Logo Opportunities center on frontline immunotherapy combinations, biomarker and companion diagnostics, AI-enabled pathology, minimally invasive screening, precision therapies for uterine sarcomas, and tele-oncology expansion in u... Full story

Yahoo Finance • 26 days ago

Myriad Genetics Q2 Loss Narrows; Revenue Falls 11%

(RTTNews) - Myriad Genetics, Inc. (MYGN) on Thursday reported a narrower loss for the second quarter despite a 11% decline in revenue, as last year's results were affected by a hefty goodwill impairment charge. The molecular diagnostics co... Full story

Yahoo Finance • 26 days ago

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

Highlights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is engaging payers and executing revenue cy... Full story

Yahoo Finance • last month

Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1

Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1 Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sector. Today we are looking at Gil... Full story

Yahoo Finance • 2 months ago

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer

SALT LAKE CITY, July 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces newly published data from the largest individual-patient-data meta-a... Full story

Yahoo Finance • 2 months ago

1 Unpopular Stock That Should Get More Attention and 2 We Find Risky

1 Unpopular Stock That Should Get More Attention and 2 We Find Risky Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about... Full story

Yahoo Finance • 2 months ago

Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication

SALT LAKE CITY, June 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces expanded availability of Precise MRD™, broadening availability to p... Full story

Yahoo Finance • 3 months ago

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

SALT LAKE CITY, May 26, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test at the end of this month. Prolaris wi... Full story

Yahoo Finance • 3 months ago

Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life

SALT LAKE CITY, May 15, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, joins forces with Nobody Wants This actress Jackie Tohn to raise awareness about the... Full story

Yahoo Finance • 3 months ago

Myriad Genetics Inc. (MYGN): Larry Robbins Likes This Stock

We just covered 10 Stocks That Tanked: Why Larry Robbins’ Top Picks Are Struggling in 2026 and Myriad Genetics, Inc. (NASDAQ:MYGN) ranks 8th on this list. Myriad Genetics, Inc. (NASDAQ:MYGN) has been a staple in the 13F portfolio of Glenv... Full story

Yahoo Finance • 4 months ago

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

SALT LAKE CITY, April 30, 2026 (GLOBE NEWSWIRE) -- The latest GeneSight® Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, reveals that... Full story

Yahoo Finance • 5 months ago

Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting

Myriad Genetics, Inc. SALT LAKE CITY, April 09, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that it will share new data at the Society of... Full story

Yahoo Finance • 5 months ago

Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as investors reacted to escalating uncertainty tied to the U.S.-Iran conflict and poli... Full story

Yahoo Finance • 5 months ago

Liquid Biopsy Products Market Report 2026-2031 Featuring Analysis of Roche, Illumina, Qiagen, MDxHealth, Novogen, BGI, Myriad Genetics and More

Company Logo Dublin, March 20, 2026 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Product Market Report: Trends, Forecast and Competitive Analysis to 2031" has been added to ResearchAndMarkets.com's offering. The global liquid biopsy product m... Full story

Yahoo Finance • 5 months ago

Myriad Genetics Gains FDA Nod For Ovarian Cancer Test

(RTTNews) - Myriad Genetics, Inc., (MYGN) announced that the U.S. FDA has approved its MyChoice CDx Test as the companion diagnostic for Zejula, a PARP inhibitor developed by GSK, for patients with advanced ovarian cancer. The approval is... Full story

Yahoo Finance • 5 months ago

2 High-Flying Stocks with Competitive Advantages and 1 We Brush Off

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns whe... Full story

Yahoo Finance • 5 months ago

Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc

Check out the companies making headlines yesterday: nLIGHT (NASDAQ:LASR): Laser company nLIGHT (NASDAQ:LASR) rose by 5.5% on Tuesday after the market reacted to the company's successful pivot into the high-growth sectors of AI infrastruct... Full story

Yahoo Finance • 6 months ago

Myriad Genetics (MYGN) Shares Skyrocket, What You Need To Know

What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 6.9% in the afternoon session after its President and CEO, Samraat Raha, purchased a significant amount of company stock. According to filings, Raha bou... Full story